Immunotherapy News and Research

Latest Immunotherapy News and Research

Obesity in African-American men increases prostate cancer risk

Obesity has a profoundly different effect on prostate cancer risk in African-American as compared to non-Hispanic white men. Obesity in black men substantially increases the risk of low- and high-grade prostate cancer, while obesity in white men moderately reduces the risk of low-grade cancer and only slightly increases the risk of high-grade cancer, according to the first large, prospective study to examine how race and obesity jointly affect prostate cancer risk.

16 Apr 2015

Yale University launches clinical study to evaluate personalized medicine for metastatic melanoma

Yale University has launched a multicenter clinical trial, sponsored by Stand Up to Cancer and Melanoma Research Alliance, that will apply the latest in personalized medicine technology to treat metastatic melanoma. The trial, for which Yale is a lead site, will enroll patients lacking a particular genetic mutation for whom immune therapy did not work or was not an option.

16 Apr 2015

Experts to make roadmap for future research, clinical trials for SCLC patients at IASLC workshop

Small cell lung cancer (SCLC) will be the concentrated focus when 100 global experts in the field meet for a workshop hosted by the International Association for the Study of Lung Cancer on April 22-24, 2015 at Memorial Sloan Kettering Cancer Center in New York City.

15 Apr 2015

MSK begins CAR T cell clinical trial for children with relapsed or treatment-resistant ALL

Researchers from Memorial Sloan Kettering Cancer Center are pioneering a new groundbreaking clinical trial for children and young adults with relapsed or treatment-resistant acute lymphocytic leukemia (ALL) by using one of the most promising methods of cancer treatment today, chimeric antigen receptor (CAR) T cells.

12 Apr 2015

Portions of female reproductive tract likely to be infected by HIV, shows study

A Dartmouth study led by Charles Wira, PhD, with first author Marta Rodriguez-Garcia, MD, PhD, found that some portions of the female reproductive tract (FRT) are more likely to be infected by HIV, particularly the ectocervix compared to the endometrium.

10 Apr 2015

Administration of selenide protects heart tissue post cardiac arrest, shows study

Damage to heart muscle from insufficient blood supply during cardiac arrest and reperfusion injury after blood flow is restored can be reduced by nearly 90 percent if selenide, a form of the essential nutrient selenium, is administered intravenously in the wake of the attack, according to a new preclinical study by researchers at Fred Hutchinson Cancer Research Center.

10 Apr 2015

People with high-risk tumors containing BRAF or NRAS gene mutations have lower survival rates

Researchers from the UNC Lineberger Comprehensive Cancer Center analyzed hundreds of melanoma samples to find out if two genetic mutations more commonly found in melanoma tumors were associated with lower survival rates in patients.

9 Apr 2015

USPTO issues Cardio3 BioSciences Notice of Allowance for patent covering CAR-expressing TCR-deficient T-Cells

Cardio3 BioSciences, a leader in engineered cell therapies with clinical programs initially targeting indications in cardiovascular disease and oncology, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a significant patent application covering T-Cell receptor-deficient T-Cells which are engineered to express a chimeric antigen receptor.

9 Apr 2015

Study suggests possibility of developing personalized treatments for brain cancer

DNA mutations can cause cancer but in some cases, more mutations may mean a better prognosis for patients. A Yale-led comprehensive genomic analysis of more than 700 brain tumors has revealed one such subtype of the most malignant brain tumor, called glioblastoma, or GBM. This subtype possesses thousands of tumor-specific DNA errors or mutations instead of dozens observed in most glioblastoma cases. It is also associated with longer survival.

8 Apr 2015

CXCR3 molecule is key mediator of melanoma metastasis, shows research

In a unique partnership demonstrating excellence in "team science," Dartmouth investigators from Norris Cotton Cancer Center identified a role for the molecule CXCR3 (widely known to regulate the migration of immune cells) as a key mediator of melanoma metastasis.

7 Apr 2015

MabVax closes $11.6 million in private placement

MabVax Therapeutics Holdings, Inc., a clinical-stage cancer immunotherapy company, is pleased to announce that it has closed on gross proceeds of approximately $11.6 million in a private placement (the "Private Placement") led by OPKO Health, Inc. and Dr. Phillip Frost, CEO and Chairman of OPKO Health.

6 Apr 2015

Personalized cancer vaccines can be used to marshal powerful immune response

Personalized melanoma vaccines can be used to marshal a powerful immune response against unique mutations in patients' tumors, according to early data in a first-in-people clinical trial at Washington University School of Medicine in St. Louis.

6 Apr 2015

Astellas Pharma, MD Anderson sign option agreement to research and develop new treatment for AML

Astellas Pharma Inc. and The University of Texas MD Anderson Cancer Center today announced the signing of an option agreement to research and develop a new treatment for patients with acute myeloid leukemia (AML).

6 Apr 2015

Clinical trial uses personalized cellular therapy to treat GVHD complication of bone marrow transplant

An innovative clinical trial using the science of "personalized" cellular therapy has begun enrolling children and adults suffering from graft-versus-host-disease (GVHD), a life-threatening complication of bone marrow transplantation in which donor immune lymphocytes attack the organs of the bone marrow transplant recipient.

3 Apr 2015

Nanoparticle technique inhibits tumor growth, prolongs survival in animal models

Delving into the world of the extremely small, researchers are exploring how biodegradable nanoparticles can precisely deliver anticancer drugs to attack neuroblastoma, an often-deadly children's cancer.

3 Apr 2015

NIH approves $6.6 million in funding for Phase 2a adult eradication study of Argos' AGS-004

Argos Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis technology platform, today announced that the NIH Division of AIDS (DAIDS) has approved $6.6 million in funding for an investigator-initiated Phase 2a adult eradication study of AGS-004, the company’s investigational fully personalized immunotherapy for HIV.

2 Apr 2015

New faculty members join UNC Lineberger to help launch immunotherapy clinical trials

Two new faculty members have joined the UNC Lineberger Comprehensive Cancer Center to help launch groundbreaking immunotherapy clinical trials testing an experimental treatment in which patients' own immune cells are genetically engineered to fight their cancer.

30 Mar 2015

Immunotherapy News and Research

Latest Immunotherapy News and Research

Obesity in African-American men increases prostate cancer risk

Yale University launches clinical study to evaluate personalized medicine for metastatic melanoma

Experts to make roadmap for future research, clinical trials for SCLC patients at IASLC workshop

MSK begins CAR T cell clinical trial for children with relapsed or treatment-resistant ALL

Portions of female reproductive tract likely to be infected by HIV, shows study

Administration of selenide protects heart tissue post cardiac arrest, shows study

People with high-risk tumors containing BRAF or NRAS gene mutations have lower survival rates

USPTO issues Cardio3 BioSciences Notice of Allowance for patent covering CAR-expressing TCR-deficient T-Cells

Study suggests possibility of developing personalized treatments for brain cancer

CXCR3 molecule is key mediator of melanoma metastasis, shows research

MabVax closes $11.6 million in private placement

Personalized cancer vaccines can be used to marshal powerful immune response

Astellas Pharma, MD Anderson sign option agreement to research and develop new treatment for AML

Clinical trial uses personalized cellular therapy to treat GVHD complication of bone marrow transplant

Nanoparticle technique inhibits tumor growth, prolongs survival in animal models

NIH approves $6.6 million in funding for Phase 2a adult eradication study of Argos' AGS-004

New faculty members join UNC Lineberger to help launch immunotherapy clinical trials

CRT, BioInvent, and University of Southampton partner to develop new immunotherapy treatments for cancer

Iron oxide nanoparticles selectively target cell surface markers in tumor microenvironments

Women face Lymphangioleiomyomatosis risk during their childbearing years

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Immunotherapy News and Research

Latest Immunotherapy News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in